Drug Type Small molecule drug |
Synonyms Irsenontrine, Irsenontrine maleate + [5] |
Target |
Mechanism PDE9A inhibitors(Phosphodiesterase 9A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H26N4O7 |
InChIKeyAFKSGMDXSLTKSU-DASCVMRKSA-N |
CAS Registry1630083-70-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Parkinson Disease | Phase 3 | - | - | |
Dementia due to Parkinson's disease | Phase 2 | US | 25 Feb 2021 | |
Dementia due to Parkinson's disease | Phase 2 | CA | 25 Feb 2021 | |
Lewy Body Disease | Phase 2 | IT | 19 Apr 2018 |
Phase 2 | 34 | (DLB Without Amyloid Copathology) | clwmvuxros(mdgwmbfwfx) = etqgenoleh xhtnhxcxpz (bugllywivh, ycgsyuwtpj - ernkcjfhcd) View more | - | 26 Sep 2022 | ||
(DLB With Amyloid Copathology) | clwmvuxros(mdgwmbfwfx) = banjtjhkqi xhtnhxcxpz (bugllywivh, jruywniymu - wnzfaeqggt) View more | ||||||
Not Applicable | - | yrtdmgztud(ulcmrvoabi) = gnadrgcxkl aqzkwplrqe (fclziilfzf ) | - | 01 Jul 2018 |